The aim of this study was to examine the expression of tenascin-C, matrilin-2, and aggrecan in irreversible corneal endothelial pathology such as pseudophakic bullous keratopathy (PBK) and Fuchs’ endothelial corneal dystrophy (FECD), which most frequently require corneal transplantation. This evidence concerns the gene MATN2 and Fuchs endothelial corneal dystrophy.